FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx

On November 14, 2022, the U.S Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx for adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

For more information, read the FDA announcement and the ImmunoGen announcement. 

Posted 11/15/22